Department of Laboratory Medicine, University of Washington, Seattle, WA.
Department of Genome Sciences, University of Washington, Seattle, WA.
Clin Chem. 2018 Jun;64(6):950-958. doi: 10.1373/clinchem.2017.285981. Epub 2018 Apr 9.
Microsatellite instability (MSI) is an emerging actionable phenotype in oncology that informs tumor response to immune checkpoint pathway immunotherapy. However, there remains a need for MSI diagnostics that are low cost, highly accurate, and generalizable across cancer types. We developed a method for targeted high-throughput sequencing of numerous microsatellite loci with pan-cancer informativity for MSI using single-molecule molecular inversion probes (smMIPs).
We designed a smMIP panel targeting 111 loci highly informative for MSI across cancers. We developed an analytical framework taking advantage of smMIP-mediated error correction to specifically and sensitively detect instability events without the need for typing matched normal material.
Using synthetic DNA mixtures, smMIPs were sensitive to at least 1% MSI-positive cells and were highly consistent across replicates. The fraction of identified unstable microsatellites discriminated tumors exhibiting MSI from those lacking MSI with high accuracy across colorectal (100% diagnostic sensitivity and specificity), prostate (100% diagnostic sensitivity and specificity), and endometrial cancers (95.8% diagnostic sensitivity and 100% specificity). MSI-PCR, the current standard-of-care molecular diagnostic for MSI, proved equally robust for colorectal tumors but evidenced multiple false-negative results in prostate (81.8% diagnostic sensitivity and 100% specificity) and endometrial (75.0% diagnostic sensitivity and 100% specificity) tumors.
smMIP capture provides an accurate, diagnostically sensitive, and economical means to diagnose MSI across cancer types without reliance on patient-matched normal material. The assay is readily scalable to large numbers of clinical samples, enables automated and quantitative analysis of microsatellite instability, and is readily standardized across clinical laboratories.
微卫星不稳定性 (MSI) 是肿瘤学中一种新兴的可操作表型,可提示肿瘤对免疫检查点途径免疫治疗的反应。然而,仍然需要具有成本效益、高度准确且可推广至多种癌症类型的 MSI 诊断方法。我们开发了一种使用单分子分子反转探针 (smMIP) 对具有泛癌信息的众多微卫星位点进行靶向高通量测序的方法,用于 MSI。
我们设计了一个针对 111 个高信息量微卫星位点的 smMIP 面板,这些位点在癌症中具有 MSI 信息。我们开发了一种分析框架,利用 smMIP 介导的纠错专门且敏感地检测不稳定事件,而无需对匹配的正常材料进行分型。
使用合成 DNA 混合物,smMIP 对至少 1% 的 MSI 阳性细胞敏感,并且在重复实验中高度一致。鉴定出的不稳定微卫星的分数可区分具有 MSI 的肿瘤与缺乏 MSI 的肿瘤,在结直肠癌 (100%诊断敏感性和特异性)、前列腺癌 (100%诊断敏感性和特异性) 和子宫内膜癌 (95.8%诊断敏感性和 100%特异性) 中具有很高的准确性。MSI-PCR 是目前 MSI 的标准分子诊断方法,对结直肠癌肿瘤同样稳健,但在前列腺癌 (81.8%诊断敏感性和 100%特异性) 和子宫内膜癌 (75.0%诊断敏感性和 100%特异性) 中存在多个假阴性结果。
smMIP 捕获提供了一种准确、诊断敏感且经济的方法,可在不依赖患者匹配正常材料的情况下诊断多种癌症类型的 MSI。该测定法易于扩展到大量临床样本,能够实现微卫星不稳定性的自动化和定量分析,并且易于在临床实验室之间标准化。